Geroncellbein (CEO Deok-gyu Kim), a specialized pharmaceutical manufacturing company, announced on the 14th that it will hold the '2026 2nd PDRN Symposium' at the Daeyang AI Center of Sejong University in Seoul on February 22nd.
This symposium will share the latest research trends and clinical outcomes of polydeoxyribonucleotides (PDRN) and discuss practical applications in dental clinical practice, regenerative medicine, osteoimmunology, aesthetics, and anti-aging. It will also include practical sessions that can be immediately applied by both general practitioners and clinicians.
The symposium will feature speakers from faculty and directors of leading domestic medical institutions, covering a wide range of topics, including the clinical applications of the PDRN injection "Celvein," a second clinical case, applications in osteoimmunology, clinical trials in dental regeneration, and anti-aging applications. In the final session, Kim Deok-gyu, CEO of GeronCelvein, will present strategies for utilizing Celvein in the anti-aging market.
CEO Kim Deok-gyu stated, “PDRN is a material with great potential for clinical application in the fields of dentistry and regenerative medicine,” and added, “This symposium will provide practical assistance to medical professionals by sharing not only theory but also actual clinical results and application know-how.”
- See more related articles
You must be logged in to post a comment.